Enanta Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 73.32. In total, the insiders bought 1 397 342 and sold 293 382 ENTA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
73.32
Buy 1 397 342 Shares
Sell 293 382 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 17, 2024 Common Stock Sell Kieffer Tara Lynn 7 266
Apr 29, 2024 Stock Option (right to buy) Buy Kowalsky Matthew Paul 150 000
Apr 29, 2024 Buy Kowalsky Matthew Paul 0
Mar 06, 2024 Stock Option (right to buy) Buy Vance Terry 15 700
Mar 06, 2024 Stock Option (right to buy) Buy Russell Lesley 15 700
Mar 06, 2024 Stock Option (right to buy) Buy Peterson Kristine 15 700
Mar 06, 2024 Stock Option (right to buy) Buy Hata Yujiro S 15 700
Mar 06, 2024 Stock Option (right to buy) Buy Foletta Mark G 15 700
Mar 06, 2024 Stock Option (right to buy) Buy Carter Bruce L A 15 700
Feb 26, 2024 Stock Option (Right to Buy) Sell Gardiner Nathaniel S. 5 187
Feb 26, 2024 Common Stock Buy Gardiner Nathaniel S. 5 187
Feb 12, 2024 Common Stock Buy Luu Brendan 3 320
Feb 12, 2024 Common Stock Sell Luu Brendan 973
Feb 12, 2024 Common Stock Buy Kieffer Tara Lynn 3 320
Feb 12, 2024 Common Stock Sell Kieffer Tara Lynn 973
Feb 12, 2024 Common Stock Buy Gardiner Nathaniel S. 3 320
Feb 12, 2024 Common Stock Sell Gardiner Nathaniel S. 973
Feb 12, 2024 Common Stock Buy Rottinghaus Scott T. 2 576
Feb 12, 2024 Common Stock Sell Rottinghaus Scott T. 755
Feb 12, 2024 Common Stock Buy Or Yat Sun 3 680
Feb 12, 2024 Common Stock Sell Or Yat Sun 1 080
Feb 12, 2024 Common Stock Buy Mellett Paul J 3 320
Feb 12, 2024 Common Stock Sell Mellett Paul J 973
Feb 12, 2024 Common Stock Buy Luly Jay R. 5 400
Feb 12, 2024 Common Stock Sell Luly Jay R. 1 584
Click to get the best stock tips daily for free!

About Enanta Pharmaceuticals

Enanta Pharmaceuticals Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro... ENTA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT